Trial Profile

Human abuse potential Study Evaluating REL-1017 vs Ketamine for Abuse Potential

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Esmethadone (Primary) ; Ketamine
Indications Major depressive disorder
Focus Therapeutic Use
Sponsors Relmada Therapeutics

Most Recent Events

04 Apr 2022 According to a Relmada Therapeutics media release, data from the study will be presented at the Ketamine & Related Compounds International Hybrid Conference 2022.
23 Mar 2022 According to a Relmada Therapeutics media release, data presented at the 60th Annual Meeting of the American College of Neuropsychopharmacology.
23 Mar 2022 According to a Relmada Therapeutics media release, data published in the peer-reviewed American Journal of Psychiatry.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com